ASLAN Pharmaceuticals to Participate in Fireside Chat at the H.C. Wainwright Autoimmune Inflammatory Disease Virtual Conference
ASLNDelisted Stock | USD 0.60 0.03 4.76% |
About 62% of Aslan Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Aslan Pharmaceuticals suggests that many traders are alarmed regarding Aslan Pharmaceuticals' prospects. Aslan Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Aslan Pharmaceuticals. Many technical investors use Aslan Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Aslan |
SAN MATEO, Calif. and SINGAPORE, March 22, 2023 -- ASLAN Pharmaceuticals , a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will be available for one-on-one meetings and participate in a fireside chat at the H.C. Wainwright Autoimmune Inflammatory Disease Virtual Conference being held on March 30, 2023. Details for the fireside chat are as follows
Read at finance.yahoo.com
Aslan Pharmaceuticals Fundamental Analysis
We analyze Aslan Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aslan Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aslan Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Aslan Pharmaceuticals is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Aslan Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aslan Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aslan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aslan Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Aslan Pharmaceuticals Related Equities
ANTX | AN2 Therapeutics | 21.90 | ||||
GLUE | Monte Rosa | 13.72 | ||||
LYRA | Lyra Therapeutics | 10.53 | ||||
IOBT | IO Biotech | 4.71 | ||||
CMPX | Compass Therapeutics | 4.49 | ||||
CTMX | CytomX Therapeutics | 3.92 | ||||
CGEM | Cullinan Oncology | 2.75 | ||||
ADAG | Adagene | 1.30 | ||||
ASMB | Assembly Biosciences | 1.25 | ||||
AGIO | Agios Pharm | 1.24 | ||||
ACHL | Achilles Therapeutics | 0.93 | ||||
ACRV | Acrivon Therapeutics, | 0.80 | ||||
ANEB | Anebulo Pharmaceuticals | 0.70 | ||||
AVTE | Aerovate Therapeutics | 0.38 | ||||
IVA | Inventiva | 1.12 | ||||
GPCR | Structure Therapeutics | 1.78 | ||||
ERAS | Erasca | 2.05 | ||||
MLYS | Mineralys Therapeutics, | 2.59 | ||||
NAMS | NewAmsterdam Pharma | 4.57 | ||||
TIL | Instil Bio | 9.39 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Aslan Stock
If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |